An asthma medication improves asthma control, respiratory quality of life, and upper airway symptoms in patients with chronic ...

Nasal polyps are noncancerous growths that can form when your nasal passages and sinuses get inflamed. Small polyps may not cause any symptoms, but they can cause issues as they grow and multiply ...

PHOENIX – Patients who have nasal polyps appeared to get symptom relief when treated with omalizumab (Xolair) regardless of comorbid asthma, according to a post-hoc trial analysis. All patients taking ...

A comparison of type 2 biologics indicated for the treatment of chronic rhinosinusitis with nasal polyps identified dupilumab as the most effective drug in decreasing nasal polyp score and nasal ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Short-term exposure to several different types of air pollution was found to significantly increase disease severity in patients with chronic rhinosinusitis with nasal polyps. Exposure to air ...

Please provide your email address to receive an email when new articles are posted on . IL-4, IL-5 and IL-13 cytokines characterize the type 2 inflammatory signature found in most patients with CRSwNP ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is the first treatment in the U.S. for CRSwNP for adolescents. The approval is supported by data from ...

Competition among biologics that target inflammatory respiratory disease is heating up even further. On Thursday, AstraZeneca said its Fasenra, used in tandem with standard steroids, significantly ...

Chronic rhinosinusitis (CRS) is a highly prevalent and debilitating inflammatory condition that affects the sinuses and nasal cavity, impacting approximately 1 in 8 people globally. 1,2 It is ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) and Amgen’s TEZSPIRE® (tezepelumab ...